Simulations Plus, Inc. (NASDAQ:SLP) Director Sells $792,600.00 in Stock

Simulations Plus, Inc. (NASDAQ:SLP) Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $39.63, for a total value of $792,600.00. Following the completion of the transaction, the director now owns 3,521,592 shares of the company’s stock, valued at approximately $139,560,690.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Simulations Plus Stock Down 3.5 %

SLP opened at $38.60 on Monday. The firm’s 50 day moving average is $44.25 and its 200-day moving average is $43.92. Simulations Plus, Inc. has a 52-week low of $32.69 and a 52-week high of $52.69. The firm has a market capitalization of $772.39 million, a P/E ratio of 80.42 and a beta of 0.72.

Simulations Plus (NASDAQ:SLP) last released its quarterly earnings results on Tuesday, July 2nd. The technology company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.04. The firm had revenue of $18.54 million for the quarter, compared to the consensus estimate of $17.92 million. Simulations Plus had a net margin of 14.36% and a return on equity of 7.80%. The firm’s quarterly revenue was up 14.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.20 EPS. Equities analysts expect that Simulations Plus, Inc. will post 0.52 earnings per share for the current fiscal year.

Simulations Plus Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 5th. Shareholders of record on Monday, July 29th will be paid a dividend of $0.06 per share. The ex-dividend date of this dividend is Monday, July 29th. This represents a $0.24 dividend on an annualized basis and a yield of 0.62%. Simulations Plus’s dividend payout ratio (DPR) is presently 50.00%.

Hedge Funds Weigh In On Simulations Plus

A number of institutional investors have recently made changes to their positions in the business. EntryPoint Capital LLC bought a new stake in shares of Simulations Plus in the first quarter worth $57,000. Allspring Global Investments Holdings LLC acquired a new position in Simulations Plus during the 1st quarter worth $70,000. Connecticut Wealth Management LLC acquired a new position in Simulations Plus during the 1st quarter worth $204,000. Janney Montgomery Scott LLC bought a new stake in shares of Simulations Plus in the 1st quarter worth about $208,000. Finally, Canton Hathaway LLC raised its stake in shares of Simulations Plus by 25.0% in the 4th quarter. Canton Hathaway LLC now owns 5,000 shares of the technology company’s stock valued at $224,000 after purchasing an additional 1,000 shares in the last quarter. 78.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on SLP shares. Craig Hallum reaffirmed a “buy” rating and set a $56.00 price objective on shares of Simulations Plus in a research note on Wednesday, July 3rd. JMP Securities started coverage on shares of Simulations Plus in a research report on Tuesday, July 16th. They set a “market perform” rating for the company. Oppenheimer lifted their price target on shares of Simulations Plus from $55.00 to $65.00 and gave the company an “outperform” rating in a report on Thursday, June 13th. KeyCorp started coverage on shares of Simulations Plus in a research note on Monday, July 29th. They set an “overweight” rating and a $47.00 price objective for the company. Finally, William Blair began coverage on Simulations Plus in a research report on Friday, June 28th. They issued an “outperform” rating on the stock. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $56.00.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.